Epizyme, Inc. (NASDAQ:EPZM) Q2 2018 Earnings Conference Call - Final Transcript
Aug 02, 2018 • 08:30 am ET
Good morning. And welcome to Epizyme's Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. Please be advised, this call is being recorded at Epizyme's request.
I would now like turn the call over to Jason Fredette, Vice President, Investor Relations. You may begin.
Thank you, Operator, and good morning, everyone. Earlier today we issued a press release summarizing Epizyme's second quarter results and recent business updates. This press release is available on the Investor Center of our website at epizyme.com. On the call with me today are Epizyme's CEO, Rob Bazemore; and our Chief Business Officer, Susan Graf. Other members of the Epizyme team will join us for the Q&A session.
(Forward-Looking Cautionary Statements)
And now, let me turn the call over to Rob to begin today's discussion.
Thank you, Jason, and good morning, everyone. At Epizyme, our vision is to rewrite the treatment of cancer and other serious diseases through the development of novel epigenetic medicines. We are pioneers in this field, leading the way with our investigational treatment tazemetostat, a first-in-class oral inhibitor of EZH2 being evaluated for the treatment of hematological malignancies and solid tumors, as both a monotherapy and in combinations. We believe strongly in tazemetostat's potential to treat patients with a range of cancers.
Epizyme's ultimate goal is to bring medicines to patients that will make meaningful improvements in their lives. We have a clear set of strategic portfolio priorities that are driving our focus and our financial discipline for both the near and longer-term. The first of these priorities is advancing tazemetostat development as a monotherapy in our two lead indications, epithelioid sarcoma and follicular lymphoma, utilizing the multiple accelerated approval opportunities we believe are available to us. We are preparing for our first NDA submission in epithelioid sarcoma, a major milestone for tazemetostat and for our organization, and in FL, we are focused on defining our monotherapy registration path and initiating a combo trial.
Our second priority is to identify additional strategic combinations and indications for tazemetostat to maximize its therapeutic potential. As we advance the development of tazemetostat, we learn more about it and based on both scientific rationale and our clinical data, we believe tazemetostat holds the potential to be used in combinations with standards-of-care and other targeted agents in a number of different cancers.
Our new Chief Medical Office, Dr. Shefali Agarwal will play a critical role in this front. We are very pleased to round out our strong and highly experienced management team with the recent appointment of Dr. Agarwal. She brings nearly 20 years of clinical experience to Epizyme, with significant late-stage oncology development expertise and a strong track record of FDA engagement and she is joining us for the call this morning. Under her leadership, we intend to further build upon tazemetostat's pipeline and the product value potential by defining the next set of tazemetostat combinations and indications to explore.
Our third strategic priority